Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Durvalumab
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Lenalidomide

First Posted Date: 2016-12-28

Last Posted Date: 2023-05-22

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT03003520

Locations: 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇦🇹
Hanusch Krankenhaus, Wien, Austria
🇩🇰
Odense Universitetshospital, Odense C, Denmark

and more 17 locations

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Phase 3

Completed

Conditions: ANCA-Associated Vasculitis

Interventions: Drug: Prednisone
Drug: Avacopan
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Azathioprine

First Posted Date: 2016-12-16

Last Posted Date: 2024-01-29

Lead Sponsor: ChemoCentryx

Target Recruit Count: 331

Registration Number: NCT02994927

Locations: 🇬🇧
Clinical Trial Site, Westcliff-on-Sea, United Kingdom

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Phase 4

Conditions: Recurrent Pregnancy Loss

Interventions: Drug: Aspirin
Drug: Dydrogesterone
Drug: Heparin
Drug: Prednisone
Drug: Immunoglobulin

First Posted Date: 2016-12-13

Last Posted Date: 2017-03-08

Lead Sponsor: Shanghai First Maternity and Infant Hospital

Target Recruit Count: 500

Registration Number: NCT02990403

Locations: 🇨🇳
Shanghai first Maternity and Infant health hospital, Tong Ji University, Shanghai, China

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Phase 1

Conditions: T Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2016-12-08

Last Posted Date: 2016-12-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT02987244

Locations: 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳
Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-12-07

Last Posted Date: 2024-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 351

Registration Number: NCT02985957

Locations: 🇺🇸
Local Institution - 0078, Albany, New York, United States
🇺🇸
Local Institution - 0010, Philadelphia, Pennsylvania, United States
🇩🇰
Local Institution - 0063, Aarhus N, Midtjylland, Denmark

and more 56 locations

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2016-11-10

Last Posted Date: 2022-05-12

Lead Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Target Recruit Count: 196

Registration Number: NCT02961257

Locations: 🇫🇷
CHU Henri-Mondor, Créteil, France
🇫🇷
Hôpital Universitaire Tenon, Paris, France
🇫🇷
Institut de Cancérologie du Gard - CHU, Nîmes, France

and more 28 locations

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Phase 3

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Placebo
Drug: ibrutinib
Drug: Prednisone

First Posted Date: 2016-11-09

Last Posted Date: 2023-03-30

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 193

Registration Number: NCT02959944

Locations: 🇺🇸
Emory University, Winship Cancer Institute /ID# 1140-0033, Atlanta, Georgia, United States
🇺🇸
Stanford University/Stanford Cancer Center, Pasteur Drive /ID# 1140-0400, Stanford, California, United States
🇺🇸
Loyola University /ID# 1140-0713, Maywood, Illinois, United States

and more 99 locations

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: enzalutamide
Drug: abiraterone acetate
Drug: prednisone

First Posted Date: 2016-11-09

Last Posted Date: 2024-12-09

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 900

Registration Number: NCT02960022

Locations: 🇫🇷
Site FR33021, Bordeaux Cedex, France
🇺🇸
Site US10052, Anchorage, Alaska, United States
🇺🇸
Site US10011, Tucson, Arizona, United States

and more 232 locations